Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Advances in Therapy|February 2, 2026
Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative ReviewJohn N Allan
Best Practice & Research. Clinical Haematology|February 18, 2018
Optimal management of the young patient CLL patientJohn N Allan, Richard R Furman
Stem Cells (Dayton, Ohio)|November 12, 2013
Concise review: Leukemia stem cells in personalized medicineMonica L Guzman, John N Allan
International Journal of Hematologic Oncology|January 18, 2019
Current trends in the management of Richter's syndromeJohn N Allan, Richard R Furman
International Journal of Hematology|September 13, 2014
Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2NJohn N Allan, Kenneth D Friedman, Maria T DeSancho
ACG Case Reports Journal|October 18, 2019
Recurrent Gastrointestinal Near-Tetraploid Diffuse Large B-Cell Lymphoma Causing Intussusception and Ileal UlcerationSteven N Mathews, Rachel Niec, Susan Mathew, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma: A Comprehensive ReviewNilanjan Ghosh, John N Allan, Sabyasachi Ghosh, et al.
Blood Advances|May 12, 2025
Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLLJohn N Allan, Tao Ran, Zhijie Ding, et al.
Leukemia & Lymphoma|July 19, 2017
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabineJohn N Allan, Gail J Roboz, Gulce Askin, et al.
British Journal of Haematology|December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trialsJohn N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Pageof 6